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Fermented milk containing 
Lactobacillus paracasei subsp. 
paracasei CNCM I-1518 reduces 
bacterial translocation in rats 
treated with carbon tetrachloride
Elisabet Sánchez1,2,3,4,*, Juan C. Nieto2,4,5,*, Silvia Vidal2,4,5, Alba Santiago6, Xavier Martinez6, 
Francesc J. Sancho7, Pau Sancho-Bru3,8, Beatriz Mirelis4,9, Helena Corominola10, Candido Juá
rez2,4,5, Chaysavanh Manichanh3,6, Carlos Guarner1,2,3,4 & German Soriano1,2,3,4
Probiotics can prevent pathological bacterial translocation by modulating intestinal microbiota 
and improving the gut barrier. The aim was to evaluate the effect of a fermented milk containing 
Lactobacillus paracasei subsp. paracasei CNCM I-1518 on bacterial translocation in rats with carbon 
tetrachloride (CCl4)-induced cirrhosis. Sprague-Dawley rats treated with CCl4 were randomized into 
a probiotic group that received fermented milk containing Lactobacillus paracasei subsp. paracasei 
CNCM I-1518 in drinking water or a water group that received water only. Laparotomy was performed 
one week after ascites development. We evaluated bacterial translocation, intestinal microbiota, 
the intestinal barrier and cytokines in mesenteric lymph nodes and serum. Bacterial translocation 
decreased and gut dysbiosis improved in the probiotic group compared to the water group. The ileal 
β-defensin-1 concentration was higher and ileal malondialdehyde levels were lower in the probiotic 
group than in water group. There were no differences between groups in serum cytokines but TNF-α 
levels in mesenteric lymph nodes were lower in the probiotic group than in the water group. Fermented 
milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 decreases bacterial translocation, 
gut dysbiosis and ileal oxidative damage and increases ileal β-defensin-1 expression in rats treated with 
CCl4, suggesting an improvement in the intestinal barrier integrity.
Bacterial translocation of enteric bacteria to mesenteric lymph nodes or other extra intestinal sites can cause 
severe infections1–3. However, the interplay between these bacteria and/or their products and the host immune 
system can also contribute to the development of a proinflammatory state1–3. Inflammation is in turn related to 
multi-organ failure in critically ill patients4, to metabolic diseases and their consequences5, and to disease pro-
gression and development of complications in patients with liver diseases1–3.
The mechanisms proposed to explain pathological bacterial translocation include alterations in gut microbi-
ota, impaired intestinal barrier, and altered immune defenses1–3. Possible methods to prevent this phenomenon 
have been largely studied in experimental models of liver disease in rodents6. The administration of carbon tet-
rachloride (CCl4) is one of the most widely used experimental models of liver disease and cirrhosis7–10. Several 
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studies using this experimental model have demonstrated the high efficacy of antibiotics to decrease intestinal 
bacterial overgrowth and prevent bacterial translocation11–13. However, antibiotics favour the development of 
bacterial resistance, mainly if they are administered for long periods of time14. Therefore, alternative treatments 
have been proposed, including beta-blockers15, bile acids16, prokinetics17, antioxidants18 and probiotics10,13,18.
Probiotics are living organisms that produce a beneficial effect to the host when administered in a sufficient 
amount19. They can prevent bacterial translocation by decreasing intestinal bacterial overgrowth and improving 
intestinal barrier and immune disturbances20,21. However, previous data on the prevention of bacterial transloca-
tion with probiotics in rodents treated with CCl4 are contradictory. Although Lactobacillus GG13 and Lactobacillus 
johnsonii La122 failed to show a benefit in bacterial translocation, other studies observed a reduction in bacterial 
translocation and proinflammatory state after treatment with Bifidobacterium pseudocatenulatum CECT7765 in 
Balb/c mice10 and a multispecies probiotic combination in Sprague-Dawley rats9. These favourable results seem 
to be a consequence of an improvement in the intestinal barrier9,10.
Lactobacillus paracasei subsp. paracasei CNCM I-1518 has been shown to improve the gut barrier and to 
reduce pro-inflammatory cytokines in Peyer’s patches and bacterial translocation in experimental colitis23,24. 
However, this probiotic has not yet been evaluated in experimental cirrhosis. Actimel® (Danone, Palaiseau, 
Cedex, France) is a commercial dairy product widely used in humans that contains fermented milk with L. par-
acasei subsp. paracasei CNCM I-1518, in addition to the yogurt bacteria Streptococcus thermophilus and L. bulg-
aricus, and vitamins B6 and D.
The aim of the present study was to compare the effects of fermented milk containing L. paracasei subsp. 
paracasei CNCM I-1518 (Actimel®) with water on bacterial translocation, gut microbiota, intestinal barrier and 
inflammatory response in the experimental model of rats treated with CCl4.
Results
Fifty-four rats were included in the study. Forty-four rats were treated with CCl4 and 5 died before week 6. At 
week 6 of treatment with CCl4, the remaining thirty-nine rats were randomized into the probiotic group (n = 20) 
or the water group (n = 19). The remaining 10 rats made up the control group.
The time elapsed between randomization and the study end (death or laparotomy, performed 1 week after 
rats developed ascites) was similar in the probiotic group and in the water group (5.1 ± 0.6 vs 5.8 ± 0.8 weeks, 
P = 0.60). When considering only the rats that reached laparotomy, the time elapsed was 6.3 ± 0.7 and 6.1 ± 0.8 
weeks, respectively (P = 1).
During the study, the total dose of CCl4 received per rat was similar in the probiotic group and in the water 
group: 2873.0 ± 357.2 vs 2986.3 ± 447.4 μ L (P = 0.94).
The mean daily volume of water with probiotic treatment that the rats in the probiotic group drank was 
57.8 ± 3.3 mL/day. The mean daily volume of water that the rats in the water group drank was 27.1 ± 1.3 mL/day 
(P < 0.001 with respect to probiotic group). The mean daily volume of water that the rats in the control group 
drank was 34.6 ± 0.8 mL/day (P < 0.001 with respect to the probiotic group and P = 0.001 with respect to the 
water group).
The weight of chow that was eaten by the rats during the study was 21.3 ± 0.9 g/day in the probiotic group, 
25.9 ± 1.2 g/day in the water group (P = 0.01 with respect to probiotic group) and 29.5 ± 1.3 g/day in the control 
group (P < 0.001 with respect to probiotic group, P = 0.08 with respect to water group). Therefore, the kcals 
received with the chow were lower in the probiotic group (61.8 ± 2.8 kcal/day) than in the water group (75.1 ± 3.6, 
P = 0.01) and the control group (85.5 ± 3.9, P < 0.001, P = 0.08 with respect to water group). As the rats in the 
probiotic group received a supplementary 20.5 ± 1.2 kcal/day with the fermented milk diluted in water, the total 
kcals received by the rats did not differ between the three groups (82.4 ± 3.3 in the probiotic group, 75.1 ± 3.6 in 
the water group, and 85.5 ± 3.9 in the control group, P NS). The weight of the rats at laparotomy was also similar 
in the two groups treated with CCl4 (353.3 ± 30.9 g in the probiotic group and 388.1 ± 11.5 g in the water group, 
p = 0.39).
The estimated mean daily dose of bacteria received by rats in the probiotic group was 2.9 ± 0.1 × 109 colony 
forming units (cfu).
Probiotic treatment did not reduce mortality or ascites formation. The mortality rate during the 
study was 35% (7/20) in the probiotic group, 31% (6/19) in the water group (P = 0.8 with respect to probiotic 
group), and 0% (0/10) in the control group (P = 0.06 with respect to the other two groups). The number of rats 
that developed ascites demonstrated by paracentesis was 80% (16/20) in the probiotic group and 79% (15/19) in 
the water group (P = 0.9). The cumulative probability of developing ascites at week 18 was 88% in the probiotic 
group and 86% in the water group (P = 0.52). 
Probiotic treatment reduced bacterial translocation. Figure 1 shows the incidence of bacterial trans-
location was significantly lower in the probiotic group (7.7%, 1/13) than in the water group (54%, 7/13) (P = 0.03). 
The incidence of bacterial translocation was higher in the water group than in control rats (0%, 0/10) (P = 0.007). 
Table 1 shows the bacteria and the sites where bacteria were isolated. Escherichia coli and Enterococcus spp. were 
the most frequently detected bacteria in cirrhotic rats, mainly in the mesenteric lymph nodes.
Effect of probiotic treatment on intestinal microbiota. Figure 2 shows the concentration of entero-
bacteria and enterococci in the ileal and cecal contents in the three study groups analysed by microbial cultures. 
The two groups of rats treated with CCl4 showed higher bacterial counts than control rats. This difference was 
statistically significant for ileal (P = 0.03) and cecal enterobacteria (P = 0.01) in the probiotic group, and for ileal 
enterobacteria (P = 0.002) and enterococci (P = 0.03) and cecal enterobacteria (P = 0.02) in the water group. 
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Figure 1. Incidence of bacterial translocation. Control rats (control group) (n = 10), rats treated with CCl4 
and water (water group) (n = 19) and rats treated with CCl4 and fermented milk containing Lactobacillus 
paracasei ssp paracasei CNCM I-1518 (probiotic group) (n = 20). CCl4, carbon tetrachloride.









1 E. coli + − − − + 
2 E. coli Enterococcus spp − − − + − 
3 E. coli Enterococcus spp. + − + − − 
4 E. coli + − − − − 
5 E. coli + − − − + 
6 E. coli Enterococcus spp. + + − − − 




Enterococcus spp. + − − − + 
Table 1.  Bacteria isolated in microbiological culture from samples of homogenizate of mesenteric 
lymph nodes, ascitic fluid, pleural fluid, liver and spleen in cirrhotic rats treated with water or probiotic. 
+represents presence of bacteria in microbiological culture, and − represents absence of bacteria in 
microbiological culture. E. coli, Escherichia coli.
Figure 2. Bacterial concentration in ileal and cecal content. Control rats (control group) (n = 10), rats 
treated with CCl4 and water (water group) (n = 19) and rats treated with CCl4 and fermented milk containing 
Lactobacillus paracasei ssp. paracasei CNCM I-1518 (probiotic group) (n = 20). Values are mean ± SEM. cfu, 
colony forming units. CCl4, carbon tetrachloride.
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However, we did not observe differences between the probiotic group and the water group in any of the microbi-
ological determinations.
However, the microbiome evaluation of ileal content by 16S rRNA analysis showed at the phylum level that 
the relative abundance of Firmicutes was significantly lower in the water group than in the control and probiotic 
groups (P = 0.01; FDR = 0.07) (Fig. 3). Moreover, there was a non-significant trend to a higher abundance of 
Proteobacteria in the control and the probiotic groups than in the water group.
Probiotic treatment reduced tumor necrosis factor-alpha (TNF-α) in mesenteric lymph nodes 
but did not change serum cytokines. Figure 4a shows cytokine concentrations in mesenteric lymph 
nodes. Interleukin-6 (IL-6) (P = 0.01) and TNF-α (P = 0.001) were higher and interleukin-10 (IL-10) (P = 0.03) 
was lower in the water group than in the control group, and TNF-α was lower in the probiotic group than in 
the water group (P = 0.02). Figure 4b shows ascitic fluid cytokine concentrations. There was a trend for a lower 
TNF-α (P = 0.09) and statistically significant lower IL-10 levels (P = 0.04) in the probiotic group than in the water 
group. Figure 4c shows serum cytokine concentrations. TNF-α levels were higher in the two groups treated with 
CCl4 than in the control group (P = 0.01 with respect to the probiotic group and to the water group). No differ-
ences in serum cytokine concentrations were found between the water and the probiotic groups.
Probiotic treatment did not modify body weight and spleen/rat weight ratio. Body weight at lap-
arotomy was higher in the control group (484.2 ± 20.6 g) than in the two groups of CCl4 treated rats (P < 0.001), 
but it was similar in the probiotic group (353.3 ± 30.9 g) and in the water group (388.1 ± 11.5 g) (P = 0.39). The 
spleen/body weight ratio was lower in control rats (0.0026 ± 0.0001) than in the two groups of rats with cirrhosis 
(P = 0.001), and it was similar in the probiotic group (0.0059 ± 0.0006) and in the water group (0.0066 ± 0.0003) 
(P = 0.45).
Probiotic treatment increased β-defensin-1 and decreased malondialdehyde (MDA) in ileal 
samples. Figure 5 shows the expression of ileal occludin, claudin-4, zonula occludens-1 and β -defensin-1 
were lower in the water group than in control rats. Ileal MDA levels were higher in the water group than in 
control group. Rats receiving probiotic treatment showed an increase in ileal β -defensin-1 and a decrease in ileal 
MDA with respect to the water group (P = 0.04 and P = 0.01, respectively). There were no statistical differences 
between probiotic and water groups regarding ileal occludin, claudin-4 and zonula occludens-1. Considering all 
the rats treated with CCl4, ileal β -defensin-1 expression was lower in rats with bacterial translocation than in rats 
without (ratio 0.017 ± 0.004 vs 0.064 ± 0.018, P = 0.04). Moreover, we found a negative correlation between ileal 
β -defensin-1 and MDA (r = − 0.59, P = 0.006).
Probiotic treatment did not modify liver damage. Figure 6 shows the degree of liver damage assessed 
by the histological score, Sirius red staining and the degree of steatosis. The two groups of CCl4 treated rats had 
higher histological scores and a higher percentage of Sirius red staining than control rats. However, we did not 
find differences in these parameters between the probiotic group and the water group. We did not observe statis-
tical differences between the three groups in the degree of steatosis.
Discussion
The main finding in this study was that probiotic treatment with fermented milk containing Lactobacillus paraca-
sei subsp. paracasei CNCM I-1518 decreased bacterial translocation in rats treated with CCl4.
Previous experimental studies evaluating probiotics in rodents treated with CCl4 reported contradictory 
results. Two studies failed to show an effect of Lactobacillus GG13 or Lactobacillus johnsonii La122 on bacterial 
translocation. However, Moratalla et al.10 observed a decrease in bacterial DNA translocation in animals treated 
with Bifidobacterium pseudocatenulatum CECT7765 in an experimental model of Balb/c mice with CCl4-induced 
Figure 3. Relative abundance of the microbiome community at the phylum level. Firmicutes was shown to 
be significantly different between the water group compared to the control and the probiotic groups (P = 0.01; 
FDR = 0.07).
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cirrhosis submitted to an oral overload of E. coli. Moreover, our group recently reported a decrease in bacterial 
translocation in CCl4-treated rats receiving a multispecies probiotic mixture9.
These contradictory findings could be due to several factors. First, different probiotics may produce different 
effects in a given experimental or clinical situation16–18. Second, differences among studies in the experimental 
model and in the duration of probiotic treatment9,10,13,22 could explain some contradictory results. For the present 
study, we chose L. paracasei subsp. paracasei CNCM I-1518 because treatment with this probiotic has previ-
ously shown to reduce bacterial translocation in rats with colitis induced by the instillation of trinitrobenzene 
sulphonic acid24. With respect to the treatment schedule, we started probiotic administration at week 6 of CCl4 
administration and the rats received the probiotic until one week after development of ascites, for a mean of 6 
weeks. We used this schedule because it is similar to that used in our previous study that showed a decrease in 
bacterial translocation with a different probiotic treatment9.
Figure 4. Inflammatory response. Control rats (control group) (n = 10), rats treated with CCl4 and water 
(water group) (n = 19) and rats treated with CCl4 and fermented milk containing Lactobacillus paracasei ssp. 
paracasei CNCM I-1518 (probiotic group) (n = 20). (a) Mesenteric lymph nodes, (b) ascitic fluid, and (c) serum. 
Values are mean ± SEM. CCl4, carbon tetrachloride, IL-6, interleukin-6; TNF-α , tumor necrosis factor-alpha; 
IL-10, interleukin-10.
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Figure 5. Intestinal barrier. Control rats (control group) (n = 10), rats treated with CCl4 and water 
(water group) (n = 19) and rats treated with CCl4 and fermented milk containing Lactobacillus paracasei 
ssp. paracasei CNCM I-1518 (probiotic group) (n = 20). Western blot of ileal samples for (a) occludin, (b) 
claudin-4, (c) zonula occludens (ZO)-1 and (d) β -defensin-1, respectively, (e) ileal MDA levels, (f) correlation 
between ileal expression of β -defensin-1 and MDA, and (g) representative image of western blot of occludin, 
claudin-4, ZO-1 and β -defensin-1 in control, water or probiotic group. Values are mean ± SEM. CCl4, carbon 
tetrachloride, MDA, malondialdehyde. Cropped membranes are displayed and full-length blots are included in 
Supplementary Information.
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The decrease in bacterial translocation observed in the probiotic group in the present study could be due to 
several non-excluding mechanisms: a decrease in intestinal bacterial overgrowth, an improvement in the intes-
tinal barrier, or modulation of immune response1–3. Using microbiological culture methods, we found the intes-
tinal concentration of the bacteria most frequently translocated in our study (enterobacteria and enterococci) 
was similar in the probiotic group and in the water group. However, the 16S rRNA analysis of the ileal content 
showed a significant increase in the relative abundance of Firmicutes and a non-significant trend to a decrease in 
Proteobacteria in the probiotic group in comparison with the water group. As cirrhotic rats from the water group 
presented a decrease in Firmicutes and a trend to an increase in Proteobacteria with respect to control healthy 
Figure 6. Liver damage. Control rats (control group) (n = 10), rats treated with CCl4 and water (water group) 
(n = 19) and rats treated with CCl4 and fermented milk containing Lactobacillus paracasei ssp. paracasei CNCM 
I-1518 (probiotic group) (n = 20). (a) Histological score, (b) Sirius red staining, and (c) degree of steatosis. 
Values are mean ± SEM. CCl4, carbon tetrachloride.
www.nature.com/scientificreports/
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rats, our findings suggest that the reduction in bacterial translocation that we observed in the probiotic group is 
partially due to an improvement in the gut dysbiosis.
Dysfunction of the intestinal barrier is considered a relevant mechanism to explain pathological bacterial 
translocation1–3. Tight junctions and antimicrobial peptides are important components of the gut barrier, and 
alterations in these components may contribute to bacterial translocation1,25,26. Few data, however, are available in 
cirrhosis1,27,28. In CCl4-induced cirrhotic rats, Teltschik et al.26 observed a relationship between bacterial translo-
cation and deficiencies in the intestinal expression of Paneth cell α -defensins, mainly cryptidin 5 and 7, together 
with elevated or unchanged non-Paneth cell β -defensins expression. In the present study, we observed a decrease 
in the ileal expression of tight junction proteins, such as claudin-4, occludin and zonula occludens-1, and the 
antimicrobial peptide β -defensin-1 in the water group in comparison with control rats. Similar findings have 
been previously described by our group9. Probiotic treatment restored the decreased β -defensin-1 expression 
without significant changes in tight junction proteins. Other authors have also reported an association between 
the decrease in bacterial translocation and the increase in the expression of intestinal antimicrobial peptides, 
including β -defensin-1, in another experimental model, in mice submitted to repeated restraint stress undergo-
ing moderate exercise29. In an experimental model of dextran sulphate sodium-induced colitis in Balb/c mice, L. 
paracasei subsp. paracasei CNCM I-1518 has been observed to improve the intestinal barrier, the gut permeability 
and the expression of zonula ocludens-123.
Moreover, in the present study we found a decrease in the oxidative damage in the ileum of rats from the pro-
biotic group. Intestinal oxidative damage has been associated with impairment in the intestinal barrier, delayed 
intestinal transit time30,31, and bacterial translocation in rats treated with CCl432. Our findings suggest that the 
increase in β -defensin-1 expression and the decrease in oxidative damage in the gut barrier are relevant for 
explaining the reduction in bacterial translocation observed in the group treated with the probiotic.
Interestingly, in a previous study using the same experimental model, rats treated with a different probiotic 
mixture showed a decrease in bacterial translocation and an increase in occludin ileal expression, without changes 
in β -defensin-19. These data suggest that different probiotics could have the same effect (in this case, a decrease in 
bacterial translocation) via different mechanisms.
Pathological bacterial translocation has been related to the proinflammatory state. In our study, rats treated 
with the probiotic presented a decrease in the levels of TNF-α in mesenteric lymph nodes. Other authors have 
also observed in an experimental model of dextran sulphate sodium-induced colitis in mice, that L. paracasei 
subsp. paracasei CNCM I-1518 reduced the production of pro-inflammatory cytokines in Peyer’s patches23. This 
immune modulation could be due to the interaction between probiotic bacteria and the immune system33,34 
in mesenteric lymph nodes and/or to the decrease of bacterial translocation to the mesenteric lymph nodes by 
potentially pathogenic bacteria, such as enterobacteria and enterococci1–3. However, these changes in the mes-
enteric lymph nodes in the probiotic group were not associated with differences in the serum cytokine profile. 
Probably as a consequence of this lack of systemic effect, we did not observe significant variations either in the 
spleen/body weight ratio as a surrogate marker of portal pressure and hemodynamic disturbances, or in the 
incidence of ascites in the probiotic group with respect to the water group. In a previous study using the same 
experimental model, we observed that treatment with a different multispecies probiotic was accompanied by a 
decrease in serum TNF-α , spleen/body weight ratio and ascites formation9.
Bacterial translocation and a proinflammatory state are relevant for promoting liver damage1,3,35. In our study, 
however, in spite of the reduction in bacterial translocation observed in the probiotic group, we did not find any 
significant effect on liver damage as assessed by the histological score and collagen deposition. This finding can be 
related to the absence of an effect of the probiotic treatment on the systemic inflammatory profile.
This study has a major limitation. We wanted to evaluate a commercial dairy product that contained not only 
L. paracasei subsp. paracasei CNCM I-1518 but also the yogurt bacteria S. thermophilus and L. bulgaricus, com-
ponents resulting from milk fermentation, vitamins B6 and D, and the milk itself. We can not therefore be sure if 
the effects observed in the probiotic group are due to L. paracasei subsp. paracasei CNCM I-1518 or to any other 
components of the mixture. It has been suggested that supplementation with vitamin D can protect against bacte-
rial infections due to its immunomodulatory effects36. However, when evaluating the effects of a fermented prod-
uct it is difficult to appraise the relative contribution of the different components, some of which are generated 
during the fermentation process37. Moreover, we are aware that we induced a significant nutritional change in the 
rats in the probiotic group. These rats received double the oral volume of fluid than the rats from the water group 
received, and although the mean total daily kcals were similar, the composition of the diet in the probiotic group 
was clearly different from that in the water group. This could affect the results, as the impact of the diet on the gut 
microbiota and bacterial translocation is well known5. Finally, to avoid the risks and interference with results that 
daily instrumentation could produce in such a relatively long-term study, we did not administer the probiotic by 
gavage but ad libitum in drinking water. This could make it difficult to know the exact dose of probiotic received 
by the rats. However, we recorded the total daily volume of the probiotic treatment that the rats drank and the 
calculated mean daily amount of bacteria administered was in the range of the scheduled dose.
In conclusion, our findings show that fermented milk containing Lactobacillus paracasei subsp. paracasei 
CNCM I-1518 decreases bacterial translocation, gut dysbiosis and ileal oxidative damage and increases ileal 
β -defensin-1 expression in rats treated with CCl4.
Methods
Animals. We included Male Sprague-Dawley rats (Harlan Laboratories). They were individually caged 
and exposed to a 12:12 light/dark cycle and were on a constant room temperature of 21 °C. They were allowed 
free access to rat chow (A04, SAFE, Augy, France) and drinking water. This study was approved by the Animal 
Research Committee at the Institut de Recerca of Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) and 
by the Departament d’Agricultura, Ganaderia, Pesca, Alimentació i Medi Natural (DAAM) de la Generalitat de 
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Catalunya. Animals received human care and all methods were performed in accordance with the relevant guide-
lines and regulations according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals38.
CCl4 administration. We administered CCl4 following Runyon et al’s method39 to induce cirrhosis. Rats 
weighing 100–120 g were fed standard rodent chow (A04, SAFE, Augy, France) and treated with 1.5 mM/L pheno-
barbital (Luminal, Kern Pharma S.L., Barcelona, Spain) in drinking water to potentiate the effect of CCl4. When 
they reached a weight of 200 g, weekly doses of CCl4 (Sigma-Aldrich Química S.L., Tres Cantos, Madrid, Spain) 
were administered into the stomach using a stainless steel feeding tube (Popper and Sons, New Hyde Park, NY, 
USA) and a sterile pyrogen-free syringe (KD Medical GMBH Hospital, Berlin, Germany), without anesthesia. The 
initial dose of CCl4 was 20 μ L and subsequent doses were calculated according to the weight changes at 48 hours 
after the last dose, as previously reported8.
Experimental design. At 6 weeks, the rats under induction of cirrhosis by the administration of CCl4 were 
randomized to receive milk fermented by Lactobacillus paracasei subsp. paracasei CNCM I-1518 in drinking 
water (probiotic group) or drinking water alone (water group) until laparotomy. Another group of healthy rats 
without induction of cirrhosis receiving drinking water (control group) was also included. All the rats from the 
three groups were allowed free access to rat chow and water with or without the probiotic (probiotic group, and 
water and control groups, respectively). A group receiving non-fermented milk was not included in the present 
study because we aimed to compare probiotic administration with the standard care, and milk is not included 
in the standard care of the rats in this experimental model. Mortality and the development of ascites during the 
study were recorded. In rats receiving CCl4, laparotomy was performed one week after the development of ascites 
confirmed by paracentesis. The moment to perform the laparotomy in control rats was decided by matching with 
rats receiving CCl4.
Administration of L. paracasei subsp. paracasei CNCM I-1518. The fermented milk (Actimel®, 
Danone, Palaiseau, Cedex, France) contained the probiotic strain Lactobacillus paracasei subsp. paracasei 
CNCM I-1518 combined with two bacteria commonly used as yogurt starters, Streptococcus thermophilus and 
Lactobacillus bulgaricus. The microbial concentration of the fermented milk at the end of shelf-life met the target 
of 1 × 108 cfu/g of L. paracasei subsp. paracasei CNCM I-1518. S. thermophilus, and L. bulgaricus were also pres-
ent in the final product at levels > 107 cfu/g. The product used in this study also contained 0.42 mg of Vitamin B6 
and 0.75 μ g of vitamin D per 100 mL.
The product was diluted 1:1 with drinking water to achieve a final bacterial concentration of 0.5 × 108 cfu/mL. 
The doses were prepared in 100 mL containers every 12 hours during all the study. This schedule was chosen 
taking into account the mean daily volume of water that rats usually drink, in order to achieve the administration 
of a daily dose of probiotic of 1–5 × 109 cfu, previously used with other probiotics in experimental studies9,13,18. 
Rats drank ad libitum and the total volume of mixture they drank every 12 hours was recorded to check the dose 
of probiotic administered to rats. We also recorded daily the volume of probiotic mixture or water that the rats 
drank, the weight of chow they ate, the total kcals received, and the proportion of kcals corresponding to chow 
and to fermented milk.
Laparotomy. On the last day of the study, we performed a laparotomy under anesthesia with 10 mg/kg of 
xylacine (Rompun, Bayer, Leverkusen, Germany) and 50 mg/kg of ketamine (Ketolar, Parke-Dawis, New York, 
NY, USA) under sterile conditions. Samples of ascitic fluid, mesenteric lymph nodes, blood, liver, spleen, ileal 
stools and terminal ileal wall, cecal stools, and pleural fluid were collected in this sequence. Rats were euthanized 
using intravenous sodium thiopentate (Penthotal, Abbott Laboratories, Chicago, IL, USA). Blood samples were 
collected in BD Vacutainer tubes (BDbiosciences, San Jose, CA, USA) containing EDTA and centrifuged. The 
supernatants were recollected and frozen at − 80 °C for later analysis. The other samples were stored at − 80 °C. 
The spleen/body weight ratio was calculated and used as surrogate marker of portal hypertension32,40.
Bacterial cultures. Samples of homogenized mesenteric lymph nodes, ascitic fluid, pleural fluid, spleen 
and liver were inoculated on Columbia blood agar, Columbia CNA agar, and the chromogenic media CPS ID3 
(BioMérieux, Marcy l’Étoile, France) and incubated for 48 h at 37 °C in an aerobic atmosphere. Isolates were pre-
sumptively identified according to their growth and morphology. Bacterial translocation was considered as the 
presence of a positive culture in mesenteric lymph nodes, liver, spleen, or ascitic or pleural fluids18.
During laparotomy, samples of cecal and ileal content weighing 0.2 g were collected, homogenized and diluted 
with 2 mL of normal saline in sterile conditions. The gut bacterial concentration was quantified by performing 
serial decimal dilutions. Samples of 100 μ L of each dilution were inoculated on Columbia blood agar, Columbia 
CNA agar, and the chromogenic media CPS ID3 (BioMérieux, Marcy l’Étoile, France). After incubation for 48 h 
at 37 °C in an aerobic atmosphere, the colonies were counted. Counts are expressed as log10 cfu/g of fresh fecal 
sample with a detection limit at 103 cfu/g18.
Microbiome analysis. We analyzed the microbiome of ileal content from 33 rats (23 cirrhotic rats, n = 13 
treated with the probiotic and n = 10 treated with water; and 10 control rats). All the samples were subjected to 
genomic DNA extraction using a previously described method41. To chemically lyse the samples, we added 250 μ l 
of 4 M guanidine thiocyanate, 40 μ l of 10% N-lauroylsarcosine and 500 μ l of 5% N-lauroylsarcosine before incu-
bation at 70 °C. Further mechanical disruption was carried out using a Mini-Beadbeater-16 (Biospec Products©) 
to extract the DNA. To clear lysates, enzymatic digestion of RNA was performed by additing of 2 μ l of a 10-mg/ml 
solution of RNAase, and the resulting DNA was precipitated and further ethanol-purified. Pure DNA was 
re-suspended in 200 μ l Tris-EDTA buffer.
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To analyse bacterial composition, we subjected extracted genomic DNA to PCR-amplification of the V4 hyper-
variable region of the 16S rRNA gene as previously described41. Amplicons were purified using the QIAquick PCR 
Purification Kit (Qiagen, Barcelona, Spain) according to the manufacturer’s instructions, and further quantified 
using a NanoDrop ND-1000 Spectrophotometer (Nucliber©). The purified amplicons were pooled in equal con-
centration and finally subjected to sequencing using the Illumina Miseq platform at the Autonomous University 
of Barcelona (UAB, Spain).
For microbiome analysis, we loaded the raw sequences into the QIIME 1.9.1 pipeline and performed the 
quality filtering analysis as previously described42. After filtering, from 33 fecal samples, we obtained a total of 
496761 of high-quality sequences with a number of reads ranging from 1435 to 40735 per sample. We used the 
USEARCH43 algorithm to cluster similar filtered sequences into Operational Taxonomic Units (OTUs) based on 
a 97% similarity threshold. We then identified and removed chimeric sequences using UCHIME44. Since each 
OTU can comprise many related sequences, we picked a representative sequence from each one. Representative 
sequences were aligned using PyNAST against Greengenes template alignment (gg_13_8 release), and a taxo-
nomical assignment step was performed using the basic local alignment search tool (BLAST) to map each rep-
resentative sequence against a combined database encompassing the Greengenes and PATRIC databases. To 
correctly define species richness for the analysis of between-sample diversity, known as beta diversity, the OTU 
table was rarefied at 4849 sequences per sample.
Serum and mesenteric lymph nodes cytokine levels. Serum supernatants and extracts from mes-
enteric lymph nodes were tested for IL-6, TNF-α and IL-10 concentrations using specific ELISAs (Peprotech, 
London, UK), according to the instructions of the manufacturer. The detection limit was 30 pg/mL.
Intestinal barrier. To perform western blot analysis, protein was extracted from rat ileum using RIPA buffer 
following the protocol of the manufacturer (Sigma Aldrich, St. Louis, MO, USA). For this study, 20 μ g of proteins 
were separated on a 4–12% SDS-PAGE (Invitrogen, Camarillo, CA, USA) gel and transferred to nitrocellulose. 
Membranes were incubated overnight with antibodies to claudin-4 (Invitrogen), occludin, zonula occludens-1 
and β -defensin-1 (Antibodies-online Inc., Atlanta, GA, USA). We used appropriate secondary antibodies con-
jugated to IR-dyes 800CW goat anti-rabbit immunoglobulin G (IgG) and 680LT goat anti-mouse IgG (H + L) 
(Li-cor, Lincoln, Nebraska, USA) to visualize proteins. Proteins were then scanned using the Odyssey Imaging 
System (Li-cor). The expression of claudin-4, occludin, zonula occludens-1 and β -defensin-1 was quantified and 
normalized to β -actin using β -actin antibody (Sigma Aldrich). Oxidative damage in ileal samples was assessed 
using the determination of MDA formation by thiobarbiturate reaction32,45. The detection limit of this assay was 
0.079 nmol/mg protein.
Liver damage. Four μ m-slices from paraffin blocks were evaluated by hematoxylin-eosin staining to study 
the histological changes and by Masson’s trichrome staining to assess the severity of fibrosis. A semi-quantitative 
score was used by a single expert pathologist to blindly classify the liver samples into: 0- normal, 1- fibrosis with 
thin and incomplete fibrous tracts, 2- regeneration nodules with thin complete fibrous tracts, and 3- regeneration 
nodules and thick and complete fibrous tracts. The degree of steatosis was evaluated in: 0- normal, 1- mild steato-
sis, and 2- severe steatosis. The degree of hepatic fibrosis was estimated by calculating the percentage of the area 
stained with picro-Sirius Red (Sirius Red F3B, Gurr-BDH Lab Supplies, Poole, England). The positive stained area 
was quantified using a morphometric analysis system. Briefly, twelve images were obtained with an optic micro-
scope (Nikon Eclipse E600, Nikon Corporation, Japan) at magnification of x20. Images were imported using an 
image-analysis system (AnalySIS, Soft-Imaging System, Munster, Germany) software and automatically merged. 
The positive area was the sum of the area of all positive pixels.
Statistical analysis. Statistical analysis was performed using the SPSS statistical package (SPSS Inc. version 
17.0, Chicago, Illinois, USA). All parameters are reported as percentages and mean ± SEM. Differences between 
groups were analyzed using the Fisher’s exact test for qualitative variables. The Shapiro-Wilk test was used to 
check the normality of data distribution. The Student’s t-test was used when data were normally distributed; oth-
erwise, the non-parametric Mann-Whitney U-test was used. Correlations were calculated using Pearson’s test or 
Spearman’s test. The probability of developing ascites was assessed by Kaplan-Meier test and then compared using 
the log rank test. A two-tailed P value below 0.05 was considered statistically significant.
Specifically regarding the microbiome evaluation, statistical analyses were carried out in QIIME and in R. 
To work with normalized data, we analyzed an equal number of sequences from all groups. The Kruskal-Wallis 
one-way test of variance was used to compare the mean number of sequences of the groups. The analysis provided 
false discovery rate (FDR)-corrected P-values. FDR < 0.1 was considered significant for all tests.
Sample size was calculated according to previous data from our group15. Considering an α error of 0.05, a β 
error of 0.20, an expected percentage of bacterial translocation of 62% in the water group and of 8% in the probi-
otic group, and a 43% overall mortality during the study, we calculated that the minimal number of rats required 
in each group was 19.
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